Evofem Biosciences implements 1-for-1,500 reverse stock split
EVFM•Evofem Biosciences implemented a 1-for-1,500 reverse stock split effective November 18, 2026, reducing outstanding common shares from approximately 132,530,081 to approximately 88,353. Split-adjusted trading begins under EVFMD, with the ticker set to revert to EVFM after 20 business days.
1. Share consolidation
Evofem Biosciences implemented a 1-for-1,500 reverse stock split effective November 18, 2026. Outstanding common shares fell from approximately 132,530,081 as of November 17 to approximately 88,353. The company said the consolidation aims to ensure sufficient authorized common shares to cover shares underlying financial instruments on a fully diluted basis.
2. Trading and fractional shares
Split-adjusted trading begins on the OTC Basic Market under EVFMD, with the ticker reverting to EVFM after 20 business days. No fractional shares will be issued; holders will receive cash based on the November 17 closing price.




